Recruiting studies: Primary Membranous Nephropathy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
Phase 3 · 31 location(s) · Cerium Pharmaceuticals, Inc. · NCT05696613 Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharm
Phase 2 · 1 location(s) · Guangdong Hengrui Pharmaceutical Co., Ltd · NCT07289763 An Outcome Analysis of Primary Membranous Nephropathy
Phase N/A · 2 location(s) · Mario Negri Institute for Pharmacological Research · NCT06242327 A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
Phase 1/Phase 2 · 19 location(s) · Nkarta, Inc. · NCT06557265 A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
Phase 2/Phase 3 · 21 location(s) · Shanghai Jiaolian Drug Research and Development Co., Ltd · NCT06470191 OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)
Phase 3 · 1 location(s) · Huashan Hospital · NCT06781944 A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
Phase 2 · 43 location(s) · Climb Bio, Inc. · NCT07096843 Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pM
Phase 2/Phase 3 · 108 location(s) · Vertex Pharmaceuticals Incorporated · NCT07204275 A Real World Study About PMN
Phase N/A · 1 location(s) · Wei Chen · NCT06893328 Study of WAL0921 in Patients With Glomerular Kidney Diseases
Phase 2 · 50 location(s) · Walden Biosciences · NCT06466135 Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001
Phase 1 · 19 location(s) · Everest Medicines (China) Co.,Ltd. · NCT05800873 Atacicept in Multiple Glomerular Diseases
Phase 2 · 1 location(s) · Vera Therapeutics, Inc. · NCT06983028 Study of YK012 in Primary Membranous Nephropathy
Phase 1 · 1 location(s) · Excyte Biopharma Ltd · NCT06982729 A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous
Phase 1 · 6 location(s) · Shanghai Jiaolian Drug Research and Development Co., Ltd · NCT05668403 A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
Phase 2 · 22 location(s) · AstraZeneca · NCT07571746 National Registry of Rare Kidney Diseases
Phase N/A · 1 location(s) · UK Kidney Association · NCT06065852 Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy
Phase 4 · 1 location(s) · First Affiliated Hospital, Sun Yat-Sen University · NCT06573411 A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropath
Phase 3 · 104 location(s) · Biogen · NCT06962800 Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
Phase 2 · 40 location(s) · Alexion Pharmaceuticals, Inc. · NCT07157787 Belimumab With Rituximab for Primary Membranous Nephropathy
Phase 2 · 20 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT03949855 Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranou
Phase 4 · 1 location(s) · First Affiliated Hospital, Sun Yat-Sen University · NCT05514015

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.